NCT01515137View on ClinicalTrials.gov

Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

Erlotinib

Erlotinib (150 mg PO QD) plus sulindac (150 mg PO BID) (Arm A), Erlotinib (150 mg PO QD) (Arm B) or placebo (for Erlotinib) QD (Arm C).

DRUG

Erlotinib plus sulindac

Erlotinib (150 mg PO QD) plus sulindac (150 mg PO BID) (Arm A), Erlotinib (150 mg PO QD) (Arm B) or placebo (for Erlotinib) QD (Arm C).

DRUG

Placebo

Erlotinib (150 mg PO QD) plus sulindac (150 mg PO BID) (Arm A), Erlotinib (150 mg PO QD) (Arm B) or placebo (for Erlotinib) QD (Arm C).

Trial Locations (1)

15232

University of Pittsburgh Cancer Institute, Pittsburgh

Sponsors

Collaborators (1)

OSI Pharmaceuticals
All Listed Sponsors
collaborator

OSI Pharmaceuticals

INDUSTRY

lead

University of Pittsburgh

OTHER

NCT01515137 - Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter